Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Acoustic whole blood imaging flow cytometry for rare cell identification

Project description

Acoustic whole-blood cytometry for cancer metastasis

Breast and prostate cancer are common cancers in women and men, respectively, but both often face metastasis. The emergence of new targeted therapies has created an unmet need for improved prognostication, treatment prediction, and monitoring, where circulating tumour cell enumeration could be particularly valuable. However, these cells are rare, and classifying and counting them is highly challenging due to the overwhelming presence of other blood cells. The ERC-funded BLOODFLOW project aims to develop new tools for detecting and monitoring disease progression in patients with metastatic cancer. The project will introduce acoustic whole-blood cytometry, enabling unbiased imaging and counting of circulating tumour cells using fluorescent antibodies with minimal pre-treatment. Additionally, it will address the technical challenges associated with commercialising this technology.

Objective

This project addresses the need for new tools to detect and monitor the disease progression in patients with metastatic cancer. Breast and prostate cancer are the most common malignant cancers in women and men, respectively. Metastasis is the main threat in these cancers since it turns a curable local disease into a chronic lethal disease. With emerging new targeting therapies, there is an unmet clinical need for improved prognostication, treatment prediction and treatment monitoring, where circulating tumor cells enumeration have potential to become a valuable tool. But circulating tumor cells are very rare and the background of other blood cells is vast which makes it extremely challenging to classify and count these cells.
In the project, we will develop acoustic whole-blood cytometry. This will enable unbiased imaging and enumeration of circulating tumor cells through a panel of fluorescent antibodies with minimal pre-treatment. The vision is that the approach will become standard equipment in hospital labs in the transition to more personalized healthcare.
The project will evaluate key technical challenges on the path to commercialization. The project has strong support from an industrial partner and from clinicians and pre-clinical researchers focused on breast and prostate cancer.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

LUNDS UNIVERSITET
Net EU contribution
€ 150 000,00
Address
Paradisgatan 5c
22100 Lund
Sweden
Region
Södra Sverige Sydsverige Skåne län
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)